Скачать или смотреть Interview with Genetic Analysis CEO Ronny Hermansen

Analyst Group interview Genetic Analysis CEO Ronny Hermansen in connection the company's Q2-report.

00:07 - For those who may not yet be familiar with Genetic Analysis, could you provide a brief introduction to the company, its core activities, and the markets in which you operate?

01:07 - You recently published your quarterly report for Q2-25. How would you summarize the quarter?

02:56 - After the end of Q2-25 you announced the launch of the GA-map® MHI GutHealth as a Research Use Only (RUO) test in the USA. Could you shortly elaborate on what type of test this is, what potential do you see in the product and its strategic relevance moving forward?

04:49 - In Q2-25, you reported strong financial development, including 34% sales growth and a positive EBITDA, primarily driven by the U.S. market. However, you also mentioned that the gross margin was negatively impacted by import duties. How do you plan to manage your commercial strategy in the U.S. going forward, particularly in terms of addressing import duties and future commercial investments?

06:07 - Lastly, what would you like to highlight as particularly interesting for an investor to monitor regarding Genetic Analysis during the rest of 2025?

Read more here: https://analystgroup.se/bolag/genetic...